HC Wainwright Weighs in on Aethlon Medical FY2026 Earnings

Aethlon Medical, Inc. (NASDAQ:AEMD) – HC Wainwright cut their FY2026 earnings estimates for Aethlon Medical in a research report issued on Tuesday, February 17th. HC Wainwright analyst S. Ramakanth now forecasts that the medical equipment provider will post earnings of ($9.49) per share for the year, down from their prior forecast of ($9.00). The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Aethlon Medical’s Q4 2026 earnings at ($2.44) EPS, Q1 2027 earnings at ($0.23) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.25) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at ($0.50) EPS, FY2029 earnings at ($0.61) EPS and FY2030 earnings at ($0.30) EPS.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Thursday, February 12th. The medical equipment provider reported ($2.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.01) by ($0.44).

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $560.00.

Aethlon Medical Price Performance

Aethlon Medical stock opened at $2.01 on Thursday. Aethlon Medical has a one year low of $1.86 and a one year high of $49.58. The company’s fifty day moving average price is $2.56 and its two-hundred day moving average price is $5.92. The company has a market capitalization of $2.65 million, a price-to-earnings ratio of -0.14 and a beta of 1.60.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC bought a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical at the end of the most recent quarter. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical News Roundup

Here are the key news stories impacting Aethlon Medical this week:

• Positive Sentiment: HC Wainwright raised several multi‑quarter and multi‑year EPS forecasts (FY2027–FY2030 and a series of 2027 quarterly forecasts), signaling the firm expects gradually improved results over the medium term. This could support sentiment if Aethlon executes on its plan. HC Wainwright estimate changes
• Neutral Sentiment: A shareholder/analyst call prepared remarks transcript was published (useful for detail on strategy, pipeline and management commentary) — may inform investors but contains no immediate market-moving announcement. Shareholder/Analyst Call Transcript
• Neutral Sentiment: Daily short-interest notices flagged a “large increase” in February but the reported short‑interest figure is 0 shares and days‑to‑cover shows 0.0 — the data look inconsistent/possibly erroneous, so there is no clear short‑squeeze or added short pressure indicated by these notices.
• Negative Sentiment: Zacks Research lowered Q4 2026 and FY2026 EPS estimates materially (Q4 to roughly ($2.47) and FY2026 to ($10.40) in their model), reducing near‑term expectations and adding short‑term negative pressure on sentiment. Zacks estimate cuts
• Negative Sentiment: Recent quarterly results showed a significant EPS miss (AEMD reported a large loss vs. consensus), and consensus full‑year estimates remain negative — these fundamentals help explain continued selling pressure and depressed valuation metrics.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.